The prescreener preview is complete. You may now close the preview.
Check your eligibility now & get in touch with a study center
CHECK ELIGIBILITY
Amlitelimab is a new drug that is being developed for treating people like you with atopic dermatitis (AD). The drug is not yet approved for treating AD and it can only be used in a study like this.
The investigational medication will be injected under the skin (subcutaneously) during the study.
Ages
12 - 17
Up to 26
Length of study
Approximately 3 years
Everyone will receive the investigational medication
What type of study-related medical care is provided during the study?
All study-related medical care related to this study are provided, including study-related exams and study-related medications. There is no insurance required to participate. All study-related medical care will be explained.
Studies may also offer compensation in return for travel.
Are there rules I need to follow if I decided to participate in these studies?
Participation in this study means that you agree to follow certain study rules. Your safety and the ability of the study to produce reliable new knowledge depend on it.
- Provide truthful information about your AD and other medication conditions along with drugs that you are taking for AD and other conditions.
- Inform the study doctor before stopping or modifying your AD treatments or before starting any new treatment.
- Attend the scheduled visits and allow the study test / procedures to be performed, which may include physical exams, blood and urine tests, electrocardiograms (ECG - heart monitoring), questionnaires / diaries. Optional procedures may include skin photos.
- Inform the study doctor, as soon as possible, of any side effects or health problems that you have, even if you do not think they are because of the study.
Can I speak with someone if I have questions?
Yes, after you complete the online questionnaire and give permission to be contacted, a study representative will contact with you. You can ask questions at any time, before deciding to participate and during study conduct.
Complete this questionnaire to determine if you may be eligible to participate in this clinical study.
The prescreener preview is complete. You may now close the preview.
V1.0
Images and video property of Sanofi